Skip to Content

Arixtra 5 mg / dose Side Effects

Generic Name: fondaparinux

Note: This page contains information about the side effects of fondaparinux. Some of the dosage forms included on this document may not apply to the brand name Arixtra 5 mg / dose.

For the Consumer

Applies to fondaparinux: subcutaneous solution

In addition to its needed effects, some unwanted effects may be caused by fondaparinux (the active ingredient contained in Arixtra 5 mg / dose). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking fondaparinux:

More common:
  • Pale skin
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness
Less common:
  • Black, tarry stools
  • bladder pain
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • chest pain
  • chills
  • collection of blood under the skin
  • confusion
  • convulsions
  • cough
  • decreased or cloudy urine
  • deep, dark purple bruise
  • difficult, burning, or painful urination
  • dizziness
  • dry mouth
  • fainting or lightheadedness when getting up from a lying or sitting position
  • fever
  • frequent urge to urinate
  • increased thirst
  • irregular heartbeat
  • itching, pain, redness, or swelling at the injection site
  • loss of appetite
  • lower back or side pain
  • muscle pain or cramps
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • pinpoint red spots on the skin
  • red, tender, or oozing skin at incision
  • shortness of breath
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • sudden sweating
Incidence not known:
  • Back pain
  • bowel or bladder dysfunction
  • difficulty with swallowing
  • fast heartbeat
  • hives, itching, or skin rash
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • leg weakness
  • numbness
  • paralysis
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • tightness in the chest

If any of the following symptoms of overdose occur while taking fondaparinux, get emergency help immediately:

Symptoms of overdose:
  • Abdominal or stomach pain or swelling
  • bruising or purple areas on the skin
  • coughing up blood
  • decreased alertness
  • headache
  • joint pain or swelling
  • nosebleeds

Minor Side Effects

Some of the side effects that can occur with fondaparinux may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Difficulty having a bowel movement
  • swelling
  • trouble sleeping
Less common:
  • Acid or sour stomach
  • belching
  • diarrhea
  • heartburn
  • indigestion
  • pain
  • skin blisters
  • stomach discomfort, upset, or pain
  • tightness in the chest
  • unusual changes to site of surgery
  • wound drainage, increased

For Healthcare Professionals

Applies to fondaparinux: subcutaneous solution


The most common adverse events were bleeding events.
The most serious adverse events were bleeding complications and thrombocytopenia.[Ref]


Very common (10% or more): Anemia (19.6%)
Common (1% to 10%): Post-operative hemorrhage, major bleeding, minor bleeding, moderate thrombocytopenia, non-fatal major bleeding at surgical site, overt bleeding associated with a bleeding index of 2 or greater, prothrombin decreased, other clinically overt bleeding, bleeding
Uncommon (0.1% to 1%): Reoperation due to bleeding, non-fatal major bleeding at non-surgical site, severe thrombocytopenia, fatal bleeding, intracranial bleeding, thrombocythemia, abnormal platelets, coagulation disorder
Very rare (less than 0.01%): Hypertensive encephalopathy with intracranial bleeding, minor gastrointestinal bleeding
Postmarketing reports: Thrombocytopenia with thrombosis, aPTT elevation, intracerebral bleeding, retroperitoneal bleeding[Ref]

The majority of major bleeding events occurred during the first 4 days after surgery. Major bleeding incidence increased in patients weighing less than 50 kg and in patients with impaired renal function.[Ref]


Very common (10% or more): Fever (13.6%)
Common (1% to 10%): Edema, post-operative wound infection, wound drainage increased, surgical site reaction, pain, chest pain
Uncommon (0.1% to 1%): Edema peripheral, wound secretion
Rare (less than 0.1%): Hot flushes[Ref]


Very common (10% or more): Nausea (11.3%)
Common (1% to 10%): Constipation, vomiting, diarrhea, dyspepsia, abdominal pain
Rare (less than 0.1%): Gastritis[Ref]


Common (1% to 10%): Hematoma, bruising
Rare (less than 0.1%): Injection site reaction
Frequency not reported: Local irritation (injection site bleeding, rash, pruritus)[Ref]


Common (1% to 10%): Increases in ALT, increases in AST
Uncommon (0.1% to 1%): Hepatic function abnormal, hepatic enzymes increased
Rare (less than 0.1%): Bilirubinemia
Frequency not reported: Increases in bilirubin[Ref]


Common (1% to 10%): Hypotension, hypertension[Ref]


Common (1% to 10%): Rash, purpura, bullous eruption (includes localized blister)
Uncommon (0.1% to 1%): Pruritus
Rare (less than 0.1%): Flushing[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness
Rare (less than 0.1%): Somnolence, vertigo, fatigue, syncope
Postmarketing reports: Spinal or epidural hematoma[Ref]


Common (1% to 10%): Urinary tract infection, urinary retention
Rare (less than 0.1%): Edema genital[Ref]


Common (1% to 10%): Hypokalemia[Ref]


Common (1% to 10%): Leg pain, back pain[Ref]


Common (1% to 10%): Insomnia, confusion
Uncommon (0.1% to 1%): Anxiety[Ref]


Common (1% to 10%): Pneumonia, coughing, epistaxis
Rare (less than 0.1%): Dyspnea[Ref]


Rare (less than 0.1%): Allergic reaction
Very rare (less than 0.01%): Angioedema, anaphylactoid/anaphylactic reaction
Postmarketing reports: Serious allergic reactions[Ref]


1. "Product Information. Arixtra (fondaparinux)." Organon, West Orange, NJ.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

4. Warkentin TE, Maurer BT, Aster RH "Heparin-induced thrombocytopenia associated with fondaparinux." N Engl J Med 356 (2007): 2653-5; discussion 2653-5

5. Savi P, Chong BH, Greinacher A, et al. "Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractionated heparin." Blood 105 (2005): 139-41

Not all side effects for Arixtra 5 mg / dose may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.